On February 5, 2026, the federal government launched TrumpRx, a website that directs consumers to drug purchasing options and discount programs. The TrumpRx platform received notable prelaunch and launch coverage across national and healthcare media, which contributed to elevated consumer awareness as the site went live. TrumpRx does not sell medications directly; instead, it aggregates and routes consumers to discounted cash‑pay options negotiated under the administration’s Most-Favored-Nation (MFN) pricing agreements.
Behind the scenes, TrumpRx leverages existing industry infrastructure like GoodRx, which is an integration partner that powers pricing and coupon flows for participating manufacturers. This enables TrumpRx to list discounted cash‑pay offers that are fulfilled through manufacturer or partner platforms. TrumpRx relies on familiar coupon and direct-to-consumer infrastructure but aggregates these offers under a federal portal aligned with the MFN narrative.
What TrumpRx Includes
GLP-1 medications
The TrumpRx homepage highlights cash pay offers for GLP-1s Wegovy and Zepbound. For example, Wegovy pills are listed at $149, some Wegovy pen doses at $199, and Zepbound starter pricing begins at $299. At launch, TrumpRx prominently features these GLP-1 discounts, even though similar pricing has already been available through manufacturer programs (NovoCare and LillyDirect).
New fertility drug discounts
The most substantial new pricing introduced at TrumpRx launch applies to fertility therapies from EMD Serono. Cash prices for Gonal f, Cetrotide, and Ovidrel were reduced significantly from existing pricing in the market, with discounts ranging from 67-93%.
Other MFN aligned medications
On TrumpRx, consumers can also search for additional brand name drugs from drug manufacturers participating in MFN agreements. When a drug is selected, TrumpRx either routes the user to the relevant manufacturer platform or provides a discount card for purchase. For example, for the drug Eucrisa (Pfizer), users can download a discount card directly from TrumpRx. For Zepbound (Eli Lilly), users are directed to the Lilly Direct website for discounting.
Cost Plus Drugs not yet integrated
Although early TrumpRx communications before launch referenced a future connection with Cost Plus Drugs, that integration was not included in the initial release of TrumpRx. At this stage, TrumpRx focuses on brand name cash pay offers only, not generics.
Market Impact
With 43 drugs listed at launch, the current scope of TrumpRx reflects an early-stage version of the platform. Cash pay pricing for many medications remains relatively high, even with MFN aligned discounts. As one example, Xeljanz is listed with monthly cash pay pricing between $1,518 to $3,204. Because of the limited set of drugs and the pricing levels involved, the degree to which TrumpRx will influence pharmacy benefit utilization is still uncertain. For now, the TrumpRx platform mainly increases visibility around direct to consumer pricing for categories like GLP-1 and fertility medications.
Implications for Employers and Benefits Consultants
Interaction with PBMs: Most TrumpRx purchases do not process through PBM systems. Therefore, under typical plan structures, the transactions from TrumpRx do not count toward a member’s deductibles or out of pocket maximums, nor do the claims appear in pharmacy claims data for the plan. This separation can create gaps in visibility related to plan adherence, utilization, and potential downstream medical risk. If a measurable volume of members begins using cash pay channels, the shift may also influence rebate guarantees, financial reconciliations, and performance guarantees that rely on PBM managed claims activity.
There is one notable exception to this. A recent Federal Trade Commission settlement requires Express Scripts to treat TrumpRx purchases as accumulator-eligible. Other PBMs are not affected by this requirement at this time, which may lead to differences across plans depending on PBM partner.
Potential for Member Confusion: Because TrumpRx adds another entry point into a growing cash pay ecosystem, employers may see more member questions about how these purchases interact with deductible accumulation and reimbursement policies, particularly at the start of the plan year. Members now encounter a wide range of cash pay choices from manufacturer programs, discount card platforms, and retail offerings, and this volume of options can make it difficult to understand where to go and what each pathway means for their benefits. Clear plan language and communication about cash pay rules will be increasingly important.
TrumpRx Implications for Employer Plans
Given the growing number of cash pay options available to members, employers and benefits consultants may find it helpful to review how their plans explain cash pay purchasing and accumulator policies, and to confirm that coverage expectations for GLP-1 and fertility medications are communicated clearly. It will be important to strengthen internal processes for out–of–plan purchases to support a smoother member experience as interest in these pathways evolves.
Truveris is a pharmacy cost containment company dedicated to reducing pharmacy costs and driving transparency for employers and benefit consultants. Our proprietary, data-driven technology and deep industry expertise empower smarter pharmacy benefit decisions through contract optimization and PBM oversight. Independent and unbiased, Truveris delivers measurable savings and accountability across every pharmacy program.
